Loading...
Market
Story
U.S. FDA Approves Perioperative Opdivo for Resectable NSCLC
Oct 3, 2024, 07:24 PM
The U.S. Food and Drug Administration (FDA) has approved the perioperative treatment of neoadjuvant Opdivo® (nivolumab) and chemotherapy followed by surgery and adjuvant single-agent Opdivo for resectable non-small cell lung cancer (NSCLC). Bristol-Myers Squibb (BMY) announced that the recommended dosage for nivolumab is 360 mg every three weeks for neoadjuvant treatment and 480 mg every four weeks for adjuvant treatment. This approval is expected to provide a new standard of care for patients with resectable NSCLC, enhancing treatment outcomes and potentially improving survival rates. These advancements reflect significant progress in the treatment of lung cancer, offering new hope for patients and healthcare providers.
View original story
Similar markets
Optune Lua with PD-1/PD-L1 inhibitors • 25%
Sunvozertinib • 25%
Durvalumab with chemotherapy • 25%
Other • 25%
Novocure • 25%
AstraZeneca • 25%
Chinese Biotech Firms • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
Summit Therapeutics' ivonescimab • 25%
Merck's Keytruda • 25%
Roche's Tecentriq • 25%
Other • 25%
Yes • 50%
No • 50%
Ivonescimab > Keytruda • 25%
Ivonescimab = Keytruda • 25%
Ivonescimab < Keytruda • 25%
Neither has significant market share • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Johnson & Johnson • 25%
Pfizer • 25%
AstraZeneca • 25%
Roche • 25%